Apellis Pharmaceuticals Stock News

Related Stocks: APLS , BMRN , SRPT , XENE , ALNY , SNDX , XBI , KRYS , IOBT , XLRN , VRTX , TRIL , DCPH , BIIB , MRUS ,

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

In last trading session, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) saw 0.58 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $41.20 trading at $0.91 or 2.26% at ring of the bell on the day assigns it a market valuation of $3.87B. That closing price of APLS’s stock is … Apellis Pharmaceuticals Inc. (NASDAQ:APLS) Is 33.25% Above Its 52-Week Low, But How Long Will It Remain So? Read More »

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approve

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pr

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pre

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 10,571 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, December 22nd. The stock was sold at an average price of $47.81, for a total transaction of $505,399.51. The sale was disclosed in a filing with the SEC, which can be accessed through the […]

SG Americas Securities LLC lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 637.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 184,014 shares of the companys stock after buying an additional 159,061 shares during the period. SG Americas Securities LLC [] The post SG Americas Securities LLC Has $6.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) appeared first on ETF Daily News .

The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.

The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron Variant Vir Biotechnology, Inc.